New Delhi, 27/3 (AO Bureau): Serum Institute of India (SII) CEO Adar Poonawala said on Saturday that the clinical trial of Coronavirus vaccine Covovax has started in India. He hoped that this vaccine could be introduced by September this year.
In August 2020, the US vaccine company Novavax Inc. announced a license agreement with the Serum Institute of India. Novavax has signed this agreement for the development and commercialization of its Covid-19 vaccine ‘Candidate’ NVX-CO 2373. This vaccine will be made available to India and countries in the lower and middle-income groups.
Poonawala tweeted, “Trial of Kovovax has started in India. The vaccine is being developed in partnership with Novavax and Serum Institute. This vaccine has been tested against Kovid-19 variants in African and UK. Its total efficiency is found to be 89 percent. We hope that this vaccine will be introduced by September 2021. “